For the detection limit assessment with antigen, a plasma pool was diluted 1:10 with 1× PBS, spiked with 0–50,000 ng/ml of recombinant CNDP1 (Origene) and diluted 50× in assay buffer, yielding a spike-in sample series with 0–1000 ng/ml CNDP1. All samples were

heat treated before 45 μl were combined with 5 μl of the bead array, as described above. The apparent limit of detection was calculated using a five-parametric logistic regression as the concentration of spiked antigen corresponding to MFI values 3× standard deviation above background. A spike-in without replicates was included in the final assay of the phase IV sample collection, and detection limits were determined as 30% above the background intensity. For analysis with A2M buy CHIR-99021 Selleckchem Ipilimumab (DY1938, RnD Systems), a spike-in series with 0–100 ng/ml antigen was prepared. For each bead identity, 32 counted events were required as absolute minimum to qualify the median fluorescence intensity (MFI) for further analysis (personal communication with

Luminex Corp.). All data processing and analysis was conducted using the R environment [15]. During phases III and IV the MFI values were corrected for order in the sequential readout; within each 96-well-assay plate using Pareto scaling (phase III) denoted scaled intensity and within each 384-well-assay plate using LOESS Cediranib (AZD2171) (phase IV) denoted nMFI, and used in further statistical analysis. The variability within a measurement was evaluated with the coefficient of variation (CV) as the ratio of standard deviation and mean and protein profiles both within and between measurements were correlated using Pearson’s correlation test. The CV calculation was performed with nMFI adjusted so that the minimum intensity value per antibody equaled zero. The association of the cancer associated confounder age and also total PSA plasma concentration was tested with a generalized linear model (GLM). The association between

CNDP1 level and tumor stage was tested with a GLM including age as a covariate with data from sample sets in phases II–IV. For phase IV samples, the tumor stages were converted to integers from 1 to 3 for T0/T1, T2 and T3/T4, respectively. Furthermore Kruskal–Wallis one-way analysis of variance (KW) was used to assess the association between phase I’s PCa risk groups or phase IV’s N or M stage sample groups and CNDP1 detection level. A GLM was applied to test for T stage associated protein profiles and Kruskal–Wallis rank sum test to determine N and M stage associated protein profiles. Multiple testing was accounted for using the Benjamini and Hochberg method.